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Abstract Background: Hypertension is a common co-morbidity in patients with type 2
diabetes mellitus, and well tolerated, effective therapies are needed to achieve
guideline-recommended blood pressure (BP) goals in these patients.
Objective: The aim of this study was to present the results of a prespecified
analysis of key secondary endpoints from a 12-week, open-label, single-arm
study evaluating the efficacy and safety of olmesartan medoxomil plus hy-
drochlorothiazide (HCTZ) in patients with hypertension and type 2 diabetes.
Study Design and Methods: After a placebo run-in period, 192 patients received
olmesartan medoxomil 20mg/day for 3 weeks. If BP remained ‡120/70mmHg,
patientswere uptitrated at 3-week intervals to olmesartanmedoxomil 40mg/day,
olmesartan medoxomil/HCTZ 40/12.5mg/day, and olmesartan medoxomil/
HCTZ 40/25mg/day.
MainOutcomeMeasure: Endpoints evaluated in this analysis were the change
from baseline in mean seated cuff BP (SeBP), proportions of patients achieving
SeBP goals, and distribution of SeBP reductions.
Results: Mean SeBP was 158.1/90.0mmHg at baseline. The mean – standard
error of BP reductions at 12 weeks for systolic and diastolic BP were
21.3– 1.1mmHg and 9.8 – 0.6mmHg, respectively (p< 0.0001 for each). At
the end of the study, the proportion of patients with diabetes achieving the
recommended SeBP goal of <130/80mmHg was 41.1%.
Conclusions:Anolmesartanmedoxomil–HCTZ treatment regimen significantly
reduced BP from baseline in patients with hypertension and type 2 diabetes.
Clinical Trials Registration: ClinicalTrials.gov identifier: NCT00403481
Introduction
Hypertension is a common co-morbidity of
type 2 diabetes mellitus, affecting nearly 80% of
patients.[1] The coexistence of these two con-
ditions is particularly detrimental because of their
demonstrated association with cardiovascular
and renal disease. Each 5mmHg increase in
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seated cuff systolic blood pressure (SeSBP) or seated
cuff diastolic blood pressure (SeDBP) increases
the risk of cardiovascular disease by 20–30%.[2]
Moreover, data from observational studies have
shown that patients with both hypertension and
diabetes have an approximately 2-fold greater
risk of developing cardiovascular disease than
patients with hypertension and no diabetes.[3]
The United Kingdom Prospective Diabetes Study
(UKPDS) was the first large-scale study to dem-
onstrate a direct relationship between systolic
blood pressure (SBP) and the complications of
diabetes over time, and that intensive blood
pressure (BP) lowering was associated with clin-
ically important reductions in both diabetes-related,
and cardiovascular morbidity and mortality in pa-
tients with type 2 diabetes.[4] Consequently, BP re-
duction was suggested to be at least as important as
blood glucose control in patients with both hyper-
tension and diabetes.
The assessment of BP control typically employs
the seated cuff BP (SeBP) method, which has
demonstrated both good practicality and clinical
utility. TheAmericanDiabetes Association (ADA),
the Seventh Report of the Joint National Com-
mittee on the Prevention, Detection, Evaluation,
and Treatment of High Blood Pressure (JNC 7),
and the European Societies of Hypertension (ESH)
and Cardiology (ESC) recommend that patients
with diabetes should be treated to an SeBP goal
of <130/80mmHg, measured using an office cuff
BP device.[5-7] In recent years, the use of ambu-
latory BPmonitoring (ABPM) has increased. The
ability to continuously assess BP over a 24-hour
period during both normal daily activities as well
at night-time can improve the prediction of cardio-
vascular risk and analyze BP loads as well as
identify the presence of white coat and masked
hypertension.[8-12]
The BENIFICIARY (BENIcar safety and
efFICacy evaluatIon: An open-label, single-ARm,
titration study in patients with hypertension and
tYpe 2 diabetes) study assessed change from
baseline in mean 24-hour ambulatory BP and
achievement of ambulatory BP prespecified study
targets in patients with type 2 diabetes and hyper-
tension receiving an olmesartan medoxomil-based
treatment algorithm.[13] In addition, efficacy of the
olmesartan medoxomil-based therapy on SeBP lev-
els was measured.We report herein the secondary
efficacy endpoints from the BENIFICIARY study,
which include the change from baseline in mean
SeBP, the achievement of SeBP goals, and the
distribution of SeSBP reductions.
Patients and Methods
Themethodology for the BENIFICIARY study
has been described previously[13] and is summa-
rized here.
Study Design
BENIFICIARYwas a prospective, open-label,
multicenter, single-arm titration study. Patients
underwent a 12-week, open-label, active treatment
period beginning with olmesartan medoxomil
20mg/day following a 3- to 4-week placebo run-
in phase.[13] During the active treatment period,
patients received olmesartan medoxomil alone or
as a fixed-dose combination with hydrochlorothia-
zide (HCTZ) and were uptitrated if BP remained
‡120/70mmHg according to the following schedule:
olmesartan medoxomil 20mg (weeks 1–3); olme-
sartan medoxomil 40mg (weeks 4–6); olmesartan
medoxomil/HCTZ 40/12.5mg (weeks 7–9); olme-
sartan medoxomil/HCTZ 40/25mg (weeks 10–12).
If SeBP was <120/70mmHg, patients entered a
maintenance phase continuing on the same dos-
age. If SeBP was ‡130/80mmHg in patients in the
maintenance phase during subsequent visits, the
titration schedule was resumed, and patients con-
tinued to be uptitrated at 3-week intervals, as
necessary, if SeBP remained ‡120/70mmHg.
Patients
Main inclusion criteria included the patient hav-
ing hypertension (mean SeSBP of 140–199mmHg
andmean SeDBP £114mmHg at two consecutive
study visits during the placebo run-in phase, with
a difference in SeSBP of £10mmHg) and type 2
diabetes (current regular use of oral antidiabetes
agents; documented diabetes according to the
ADAand/orWHOcriteria; or diagnosis of diabetes
after 40 years of age [non-insulin-dependent]).
Patients were also included in the study if they
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were stable on oral antidiabetes agents for
‡4 weeks or if they had newly diagnosed or ex-
isting hypertension (>130/80mmHg) that was
uncontrolled on current antihypertensive therapy.
Finally, patients needed to have a mean day-
time (8am to 4pm) ambulatory SBP >130 and
£199mmHg, and mean daytime ambulatory dia-
stolic BP (DBP) £114mmHg, as assessed by
mean 24-hour ABPM during the placebo run-in
phase for inclusion in the active treatment phase
of the study.
The presence of any serious disorder, including
cardiovascular, renal, pulmonary, hepatic, gastro-
intestinal, endocrine/metabolic (note: patients
with non-insulin-dependent type 2 diabetes were
allowed in the study), hematologic, oncologic,
neurologic, and psychiatric diseases, overt protein-
uria, or non-dominant arm circumference <24 cm
or >42 cm, was exclusionary. Patients were re-
moved from the study and treated with appro-
priate antihypertensive therapy at the discretion
of the investigator if at any time SeBP either
became >199/114 or <120/70mmHg with symp-
tomatic hypotension. Also, patients with a fast-
ing serum glucose level of >300mg/dL or a serum
creatinine level of >1.7mg/dL at screening were
excluded from the study.
Cuff Blood Pressure Protocol
Following a 5-minute rest period, three separate
measurements were taken using an automatic
Omron BP-monitoring device (HEM-705CPII;
Omron Healthcare, Inc., Bannockburn, IL, USA),
with a full 2-minute interval between SeBP mea-
surements and with the cuff fully deflated between
measurements. The mean of the three SeBP mea-
surements constituted the SeBP value for that visit.
Efficacy Assessments
ABPM and safety data for the BENIFICIARY
study have been reported previously.[13] Second-
ary endpoints reported here include changes from
baseline in mean SeSBP and mean SeDBP at the
end of each titration period; the overall change at
the end of the 12-week active treatment period;
the number/percentage of patients achieving
SeBP goals of <130/80 and <120/80mmHg; and
the number/proportion of patients achieving
mean SeSBP reductions of £15mmHg, >15 and
£30mmHg, >30 and £45mmHg, or >45mmHg.
Statistical Analysis
All patients who received at least one dose of
the active study drug and had at least one post-
baseline BP measurement were included in the
efficacy analysis dataset. All data are reported as
mean – standard error of the mean (SEM) unless
otherwise specified. The last observation carried
forward method was used to assess the changes
from baseline in mean SeSBP and mean SeDBP.
Baseline characteristics were summarized using
descriptive statistics conducted at a two-sided sig-
nificance level of 5%. A one-sample t-test was used
for within-group change from baseline to end of
study, and the resultant mean change, standard
error, two-sided 95% confidence interval, and
p-value were provided. Summary statistics for the
primary efficacy variable were presented. Second-
ary efficacy variables were analyzed in a similar
way to the primary efficacy variable. Statistical
analyses were carried out using SAS software ver-
sion 6.12 (SAS Institute, Inc., Cary, NC, USA).
Results
Patient Disposition and Baseline
Characteristics
Of the 329 patients screened, 267 received at
least one dose of placebo run-in medication and
192 received at least one dose of active study
medication, and were considered part of the
efficacy and safety cohorts. By study end, 192 pa-
tients (100%) had received olmesartanmedoxomil
20mg/day, 182 (94.8%) had received olmesartan
medoxomil 40mg/day, 173 (90.1%) had received
olmesartan medoxomil/HCTZ 40/12.5mg/day, and
144 (75.0%) had received olmesartan medoxomil/
HCTZ 40/25mg/day. Baseline demographic data
are summarized by treatment regimen in table I.
Efficacy
The mean 24-hour ambulatory BP data for the
BENIFICIARY trial has been previously pre-
sented.[13] In the BENIFICIARY study, for the
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primary endpoint, the change from baseline in
mean 24-hour ambulatory SBP at week 12 was
20.4mmHg.
Seated Cuff Blood Pressure Measurement
At week 12, the reductions (– SEM) in mean
SeSBP and mean SeDBP were 21.3 – 1.1mmHg
and 9.8 – 0.6mmHg, respectively, for the total
cohort (both p < 0.0001 vs baseline).
Mean SeSBP was significantly decreased from
baseline by week 12 for each treatment regimen,
with reductions ranging from -9.5 – 1.0mmHg to
-21.8– 1.2mmHg (figure 1).Mean SeDBP also sig-
nificantly decreased, with reductions ranging from
-4.0– 0.6mmHg to –9.9– 0.7mmHg (figure 1).
SeSBP and SeDBP reductions were significantly
increased when HCTZ 12.5mg was added to ol-
mesartanmedoxomil 40mg in all treatment groups
(figure 1). Patients also had significant increases in
SeSBP and SeDBP reductions when titrated from
olmesartan medoxomil/HCTZ 40/12.5mg to ol-
mesartan medoxomil/HCTZ 40/25mg (figure 1).
At study end, the cumulative percentages of
patients achieving SeBP goals of <130/80mmHg
and <120/80mmHg were 41.1% and 24.0%, re-
spectively. Overall, each uptitration increased
SeBP goal achievement in the total cohort (figure 2).
The proportions of patients who achieved
mean SeSBP reductions of £15mmHg, >15 and
£30mmHg, >30 and £45mmHg, and >45mmHg
were 16.1%, 34.9%, 19.3%, and 4.7%, respective-
ly, for the maximum dose of the treatment algo-
rithm (figure 3). There was a non-statistically
significant trend between treatment and the pro-
portion of patients achieving defined SeSBP re-
ductions (i.e. increasing the dose of olmesartan
medoxomil and olmesartan medoxomil/HCTZ
resulted in more patients achieving >15mmHg
reductions in SeSBP).
A prespecified subgroup analysis of patients
with stage 1 and stage 2 hypertension showed that
the proportion of patients achieving the JNC 7
recommended BP goal of <130/80mmHg for pa-
tients with type 2 diabetes increased with upward
titration of the treatment regimen. In patients with
stage 1 hypertension, goal achievement rates were
Table I. Baseline demographics, clinical characteristics, and base-
line blood pressure (BP) informationa,b
Parameter Value









Height [cm] 168.0 – 11.3
Weight [kg] 95.2 – 23.0
HTN stagec [n (%)]
stage 1 101 (52.6)
stage 2 91 (47.4)
SeBPd [mmHg]
SeSBP 158.1 – 12.6
SeDBP 90.0 – 10.0
a Demographics were identical for efficacy and safety cohorts
(n =192).
b All data are mean– standard deviation, unless otherwise specified.
c HTN stage determined by mean cuff BP at baseline.
d Data are the average of the mean office cuff BP from last visit
before active therapy initiation (presented asmean– standard error
of the mean).
HTN=hypertension; SeBP= seated cuff blood pressure; SeDBP=







































Fig. 1. Change from baseline in seated cuff blood pressure (SeBP)
at week 12/last observation carried forward for the total cohort,
patients with stage 1 hypertension, and patients with stage 2 hy-
pertension. Data are mean – standard error of the mean. p <0.0001
for all reductions vs baseline. HCTZ= hydrochlorothiazide; OM =
olmesartan medoxomil; SeDBP = seated cuff diastolic blood pres-
sure; SeSBP = seated cuff systolic blood pressure; * p< 0.0001,
** p< 0.001, ***p < 0.01, **** p-value not significant vs preceding
treatment regimen.
254 Kereiakes & Neutel
ª 2011 Kereiakes & Neutel, publisher and licensee Adis Data Information BV. Drugs R D 2011; 11 (3)
16.8%, 29.7%, 44.6%, and 54.5% across the dos-
ing range (olmesartan medoxomil 20mg, olme-
sartan medoxomil 40mg, olmesartan medoxomil/
HCTZ 40/12.5mg, and olmesartan medoxomil/
HCTZ 40/25mg), while the goal achievement
rates for patients with stage 2 hypertension were
lower at 3.3%, 4.4%, 13.2%, and 26.4%.
Discussion
In addition to recommended lifestyle changes
to prevent or manage hypertension,[6] many pa-
tients with diabetes also require antihypertensive
medication to achieve SeBP goals.[14] Mono-
therapy comprising a renin-angiotensin system
inhibitor (either an angiotensin receptor blocker
or an ACE inhibitor) is recommended as initial
therapy.[5] The addition of agents such as a diuret-
ic or calcium channel blocker is recommended
if patients do not achieve the SeBP goal.[5] Ad-
herence with therapy, and thus therapeutic effi-
cacy, are improved through the use of fewer pills,
and switching to fixed-dose combinations is a
well proven strategy to ensure adherence.[15,16]
The present study protocol comprised a treat-
ment schedule similar to that recommended by
hypertension treatment guidelines such as JNC 7
andESH/ESC.[6,7] Dosing was intensified at 3-week
intervals in a manner consistent with the recently
revised guidelines of the American Society of
Hypertension.[17]
The time of dosing in BENIFICIARY was
in the morning hours and correlated with the
SeBP measurements.[13] It may be possible that
evening dose administration may affect the effi-
cacy of treatment with an olmesartan medoxomil-
based treatment algorithm. This has previously
been suggested by Tofe Povedano and Garcia De
La Villa,[18] who conducted a crossover design
ABPM study to determine the benefits of morning
versus evening dosing of olmesartan medoxomil
40mg on ambulatory BP, nocturnal BP fall, and
albuminuria in patients with type 2 diabetes and
newly diagnosed hypertension. These investiga-
tors demonstrated significantly greater reduc-
tions of night-time SBP (p = 0.007) and night-time

































Achieved BP goal of <130/80 mmHg
Achieved BP goal of <120/80 mmHg
Fig. 2. Cumulative seated cuff blood pressure (SeBP) goal achieve-
ment at week 12/last observation carried forward. The SeBP mea-
surements are calculated using the total number of subjects in
the treatment cohort (n=192) with the last observation carried forward
for patients who did not have a measurement at end of study.






































































OM 20 mg OM 40 mg OM/HCTZ 40/12.5 mg
SBP reduction (mmHg)
OM/HCTZ 40/25 mg
Fig. 3. The proportion of patients achieving prespecified systolic blood pressure (SBP) decreases at week 12. Percentages are calculated using
the total number of subjects in the treatment efficacy cohort as the denominator. HCTZ= hydrochlorothiazide; OM=olmesartan medoxomil.
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of olmesartan medoxomil compared with morn-
ing dosing.
The present study demonstrated that an ol-
mesartan medoxomil-based treatment algorithm
resulted in large SeBP reductions in a population
of patients with diabetes and hypertension. For
comparison, the most recent National Health and
Nutrition Examination Survey showed that be-
tween 1999 and 2004, 42% of patients in theUSwho
were diagnosed with diabetes and hypertension
achieved an SeBP goal of <130/80mmHg.[19]
The present study demonstrated a trend for
dose response-related SeBP reductions with higher
doses of olmesartan medoxomil and HCTZ when
administered either alone or in combination.
SeBP reductions were significantly greater fol-
lowing dose increments with the single exception
of the SeSBP reduction observed following titra-
tion of olmesartan medoxomil 20mg to olme-
sartan medoxomil 40mg. More than one-half of
these patients with diabetes and hypertension
experienced a >15mmHg SeSBP reduction in the
olmesartan medoxomil/HCTZ 40/12.5mg and
40/25mg groups by end of study.
It has been well documented that tight BP
control in patients with type 2 diabetes and hyper-
tension significantly reduces the risk of cardio-
vascular and renal disease as well as associated
mortality rates.[20-24] However, it has also been
shown that two or more antihypertensive agents
will be needed to achieve the SeBP goal of
<130/80mmHg in the majority of patients with
diabetes and hypertension.[6] The results reported
in the current analysis of the BENIFICIARY
study data show that an olmesartan medoxomil-
based combination therapy produced significant
BP reductions in patients with type 2 diabetes.
These results are similar to those of other studies
involving angiotensin receptor blockers, which
have demonstrated significant BP reductions and
higher goal BP achievement with dose titration
and concomitant use of HCTZ in this difficult-to-
treat patient population.[25,26]
Conclusion
Olmesartan medoxomil –HCTZ has been
shown to effectively reduce BP in patients with
hypertension and type 2 diabetes. The use of a
fixed-dose combination of olmesartan medox-
omil and HCTZ may improve BP control rates
by enabling an increased proportion of these
patients to achieve the currently recommended
SeBP goal of <130/80mmHg.
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